EUCTR2008-006947-38-GB
进行中（未招募）
1 期
A randomised double-blind placebo-controlled pilot study of D-cycloserine-augmented exposure therapy in adolescents with obsessive-compulsive disorder
King's College London (Institute of Pyschiatry)0 个研究点目标入组 24 人2009年7月9日
相关药物Cycloserine
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- King's College London (Institute of Pyschiatry)
- 入组人数
- 24
- 状态
- 进行中（未招募）
- 最后更新
- 7年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •i) DSM\-IV diagnosis of OCD
- •ii) Age 12\-18
- •iii) Referred to the National and Specialist OCD clinic at Maudsley Hospital
- •iv) If on medication, that should be stable for 12 weeks, and not be changed during the course of the trial
- •v) Provision of written informed consent (patient and carer)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
排除标准
- •i) Current diagnosis of psychosis, current alcohol or substance abuse/dependence
- •ii) English too poor to engage in treatment
- •iii) Severe disabling neurological disorder
- •iv) Medical contraindication to cycloserine, including epilepsy and porphyria
- •v) A diagnosed global learning disability or pervasive developmental disorder
- •vi) Characteristics interfering with completion of treatment eg life\-threatening or unstable medical illness
- •vii) Pregnancy
- •viii) Not suitable for CBT (selective mutism, lack of insight or motivation to change)
结局指标
主要结局
未指定
相似试验
已完成
不适用
A pilot study of D-cycloserine-augmented cognitive behavioural therapy (CBT) with exposure therapy in adolescents with obsessive-compulsive disorder (OCD)Obsessive-compulsive disorderMental and Behavioural DisordersISRCTN70977225Institute of Psychiatry, Kings College London (UK)24
进行中（未招募）
1 期
Trial of oxytocin for the treatment of emotional withdrawal symptoms and for relapse prevention in abstinent heroin dependent individualsOpioid dependence. The study will be investigating the efficacy of Syntocinon (oxytocin) on treating the withdrawal symptoms and cravings that opioid (e.g. almost always heroin) dependent individuals experience following detoxification.MedDRA version: 20.0 Level: LLT Classification code 10057379 Term: Addiction relapse System Organ Class: 100000004873MedDRA version: 20.0 Level: LLT Classification code 10001126 Term: Addiction any drug System Organ Class: 100000004873Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2014-002708-26-GBniversity of Surrey3
招募中
不适用
Immunoglobulin therapy in Lung TransplantTransplantationRespiratory - Other respiratory disorders / diseasesACTRN12618001394235The Alfred Hospital40
已完成
不适用
A randomised, double-blinded clinical study of LC for systemic lupus erythematosus patientsSystemic lupus erythematosus (SLE)Musculoskeletal DiseasesISRCTN81818883Department of Health (Taiwan) - Executive Yuan90
尚未招募
3 期
The Myer Foundation Study into Multiple SclerosisRelapsing remitting multiple sclerosisNeurological - Multiple sclerosisACTRN12606000359538Melbourne Health20